Biointron has developed our own CHOK1-Fut8KO expression platform for afucosylated antibodies.

Biointron is excited to announce our newly launched CHOK1-Fut8KO expression platform for afucosylated antibodies.

On March 21st, Biointron Biological Shanghai R&D Center welcomed AstraZeneca delegations Mark Cobbold, Margie Li, Hao Huang, and Yingjie Wu for an on-site visit.